LABA/Corticosteroid Combination Inhalers for the Treatment of Asthma

Key information on asthma combination inhalers.

Quickly compare combination inhaler options for your asthma patients with the MIMS table of LABA/corticosteroid asthma inhalers.

The table provides essential information for healthcare professionals prescribing a LABA/corticosteroid device for the first time, either when stepping up treatment in patients not adequately controlled on an inhaled corticosteroid and a short-acting β2 agonist, or when starting a combination inhaler in patients already adequately controlled on a LABA and a corticosteroid taken separately.

It is also designed to help prescribers looking for an alternative LABA/corticosteroid device where the existing choice is unsuitable.

The table lists all available combinations of the LABAs formoterol, salmeterol and vilanterol with the corticosteroids beclometasone, budesonide and fluticasone. It summarises:

  • Metered/pre-dispensed and delivered doses
  • Inhaler type (breath-actuated or pressurised metered-dose)
  • Dose counter and confirmation features
  • Compatible spacers
  • Age range for use
  • Suitability for combined maintenance and reliever therapy

Drug names link through to the full MIMS entries for more detailed prescribing information on each branded or generic product.

Recommendations are derived from manufacturers' Summaries of Product Characteristics (SPCs).

Go to the MIMS asthma combination inhalers table

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...